CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry

Description

Prospective observational registry focusing on an adolescent cohort diagnosed with severe alopecia areata,receiving routine care from dermatology providers. Visit schedules for patients will be determined by the provider in accordance with routine clinical care, and any prescriptions provided to patients will adhere to product availability and local prescribing guidelines/regulations in the country where the participating registry site is located.

Conditions

Alopecia Areata

Talk to us

Study Overview

On this page

Study Details

Study overview

Prospective observational registry focusing on an adolescent cohort diagnosed with severe alopecia areata,receiving routine care from dermatology providers. Visit schedules for patients will be determined by the provider in accordance with routine clinical care, and any prescriptions provided to patients will adhere to product availability and local prescribing guidelines/regulations in the country where the participating registry site is located.

CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry

CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry

Condition
Alopecia Areata
Intervention / Treatment

-

Contacts and Locations

Waltham

CorEvitas, LLC, Waltham, Massachusetts, United States, 02451

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Has ever been diagnosed with severe AA by a dermatologist or a qualified dermatology provider.
  • 2. Is 12-17 years of age at the time of enrollment.
  • 3. Is willing to provide consent/assent for participation in the registry.
  • 4. Has been prescribed a new commercially available advanced therapy and/or conventional systemic therapy for the treatment of severe AA in adolescents in the context of routine clinical care that is consistent with local prescribing guidelines and/or regulations for the country where the site is located.
  • 1. At the time of registry enrollment OR
  • 2. Within 6 months prior to registry enrollment In the opinion of the treating provider, is deemed a candidate for treatment with a commercially available advanced therapy and/or conventional systemic therapy for the treatment of severe AA in adolescents but has not received nor is planning to initiate treatment at the time of registry enrollment.
  • 1. Is participating or planning to participate in a blinded clinical trial for any investigational medication.
  • 2. Is unwilling or unable to provide standing height measurements.

Ages Eligible for Study

12 Years to 17 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

CorEvitas,

Study Record Dates

2099-12-31